Comments
Sharon Bio-Medicine has completed expansion of its three manufacturing facilities. According to a statement issued by the company to the exchanges, it invested about ₹125 crore for the expansion. Of this, ₹85 crore was spent on the Dehradun formulations plant. Capacity at the plant has been more than doubled. Commercial production is expected to kick off in June. At Sharon’s two other expanded plants at Taloja near Navi Mumbai, commercial production has already started. After hitting ₹43.3 in early trade, the stock closed flat at ₹41.95 on Wednesday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.